Table 1.
Species (no. of isolates) | Drug | MIC (μg/ml) |
|||||
---|---|---|---|---|---|---|---|
Range | Breakpoint interpretationa |
MIC50 | MIC90 | ||||
S | I | R | |||||
Achromobacter spp. (33) | Tetracycline | 2–256 | ≤4 | 8 | ≥16 | 256 | 256 |
Doxycycline | 0.5–64 | ≤4 | 8 | ≥16 | 16 | 64 | |
Minocycline | 0.5–16 | ≤4 | 8 | ≥16 | 2 | 8 | |
Tigecyclineb | 0.5–4 | ≤2 | 4 | ≥8 | 2 | 4 | |
Alcaligenes faecalis (11) | Tetracycline | 4–32 | ≤4 | 8 | ≥16 | 8 | 16 |
Doxycycline | 2–16 | ≤4 | 8 | ≥16 | 2 | 8 | |
Minocycline | 1–8 | ≤4 | 8 | ≥16 | 2 | 8 | |
Tigecyclineb | 1–8 | ≤2 | 4 | ≥8 | 2 | 4 | |
Burkholderia cepacia complex (21) | Tetracycline | 0.03–256 | ≤4 | 8 | ≥16 | 16 | 64 |
Doxycycline | 0.06–16 | ≤4 | 8 | ≥16 | 4 | 4 | |
Minocyclinec | 0.03–4 | ≤4 | 8 | ≥16 | 1 | 2 | |
Tigecyclineb | 0.03–2 | ≤2 | 4 | ≥8 | 0.5 | 2 | |
Chryseobacterium gleum-indologenes (11) | Tetracycline | 0.06–32 | ≤4 | 8 | ≥16 | 8 | 32 |
Doxycycline | 0.125–16 | ≤4 | 8 | ≥16 | 1 | 8 | |
Minocycline | 0.03–2 | ≤4 | 8 | ≥16 | 0.25 | 1 | |
Tigecyclineb | 0.03–4 | ≤2 | 4 | ≥8 | 1 | 4 | |
Elizabethkingia meningoseptica (15) | Tetracycline | 2–128 | ≤4 | 8 | ≥16 | 32 | 64 |
Doxycycline | 1–32 | ≤4 | 8 | ≥16 | 2 | 4 | |
Minocycline | 0.06–2 | ≤4 | 8 | ≥16 | 0.25 | 0.5 | |
Tigecyclineb | 0.25–8 | ≤2 | 4 | ≥8 | 2 | 8 | |
Stenotrophomonas maltophilia (26) | Tetracycline | 0.5–64 | ≤4 | 8 | ≥16 | 8 | 16 |
Doxycycline | 1–4 | ≤4 | 8 | ≥16 | 2 | 2 | |
Minocyclined | 0.25–2 | ≤4 | 8 | ≥16 | 0.25 | 0.5 | |
Tigecyclineb | 0.125–8 | ≤2 | 4 | ≥8 | 0.5 | 2 | |
Pseudomonas putida (11) | Tetracycline | 0.125–256 | ≤4 | 8 | ≥16 | 2 | 16 |
Doxycycline | 0.06–128 | ≤4 | 8 | ≥16 | 4 | 32 | |
Minocycline | 0.06–32 | ≤4 | 8 | ≥16 | 2 | 16 | |
Tigecyclineb | 0.25–16 | ≤2 | 4 | ≥8 | 2 | 8 | |
Pseudomonas stutzeri group (10) | Tetracycline | 0.125–8 | ≤4 | 8 | ≥16 | 0.5 | 4 |
Doxycycline | 0.25–8 | ≤4 | 8 | ≥16 | 2 | 8 | |
Minocycline | 0.5–8 | ≤4 | 8 | ≥16 | 1 | 4 | |
Tigecyclineb | 0.06–4 | ≤2 | 4 | ≥8 | 0.25 | 2 |
S, sensitive; I, intermediate; R, resistant. CLSI categories for other non-Enterobacteriaceae for tetracycline, doxycycline, and minocycline were used (susceptibility at 4 μg/ml, intermediacy at 8 μg/ml, and resistance at 16 μg/ml).
Breakpoint recommended by the U.S. Food and Drug Administration when testing Enterobacteriaceae for tigecycline (susceptibility at 2 μg/ml, intermediacy at 4 μg/ml, and resistance at 8 μg/ml).
Burkholderia cepacia CLSI breakpoint recommended for minocycline.
Stenotrophomonas maltophilia CLSI breakpoint recommended for minocycline.